- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | PEGBIO CO-B-50 (02565): INSIDE INFORMATION ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION APPLICATION BY THE COMPANY | - | HKEx | ||
| 02.04. | PEGBIO CO-B-50 (02565): VOLUNTARY ANNOUNCEMENT RESEARCH ABSTRACT RELATED TO CR059 ACCEPTED BY THE 2026 SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION ... | - | HKEx | ||
| 01.04. | PEGBIO CO-B-50 (02565): CHANGE OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 ... | - | HKEx | ||
| PEGBIO Aktie jetzt für 0€ handeln | |||||
| 23.03. | PEGBIO CO-B (02565): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025 | 2 | HKEx | ||
| 16.03. | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT PEGBIO ENTERS INTO EXCLUSIVE COMMERCIALIZATION COLLABORATION WITH TENRY PHARMACEUTICAL FOR PAIDAKANG IN MAINLAND ... | 2 | HKEx | ||
| 11.03. | PEGBIO CO-B (02565): DATE OF BOARD MEETING | 3 | HKEx | ||
| 10.03. | PEGBIO CO-B (02565): CHANGE IN BOARD LOT SIZE | - | HKEx | ||
| 06.03. | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT PEGBIO'S NEXT-GENERATION GLP-1 (CR059) COMPLETES FIRST-IN-HUMAN TRIAL WITH ONE-MONTH CLINICAL OBSERVATIONS ... | 3 | HKEx | ||
| 23.12.25 | PEGBIO CO-B (02565): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 22.12.25 | PEGBIO CO-B (02565): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 22.12.25 | PEGBIO CO-B (02565): COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE | - | HKEx | ||
| 15.12.25 | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT NOTICE ABOUT VOLUNTARY EXTENSION OF LOCK-UP PERIOD GIVEN BY A CORNERSTONE INVESTOR | 1 | HKEx | ||
| 28.11.25 | PEGBIO CO-B (02565): INSIDE INFORMATION ANNOUNCEMENT FILING WITH THE CSRC REGARDING THE APPLICATION FOR THE PROPOSED IMPLEMENTATION OF H SHARE FULL CIRCULATION | 2 | HKEx | ||
| 26.11.25 | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT NOTICE ABOUT VOLUNTARY EXTENSION OF LOCK-UP PERIOD GIVEN BY A CORNERSTONE INVESTOR | - | HKEx | ||
| 14.11.25 | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT - CHINA NMPA GRANTED APPROVAL OF NDA FOR PB-119 | - | HKEx | ||
| 03.11.25 | PEGBIO CO-B (02565): VOLUNTARY DISSOLUTION OF A SUBSIDIARY AND UPDATE ON DIRECTOR'S INFORMATION | - | HKEx |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,610 | -0,85 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| EVOTEC | 5,545 | +2,88 % | MAK Capital fordert Börsengang von Evotec-Tochter und schnellere Reformen | Der aktivistische Investor MAK Capital erhöht den Druck auf die Evotec SE und verlangt strategische sowie operative Anpassungen. Im Fokus steht ein möglicher Börsengang der US-Tochter Just Biologics... ► Artikel lesen | |
| BIONTECH | 84,15 | +0,84 % | BERENBERG stuft Biontech auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Biontech mit einem Kursziel von 155 US-Dollar auf "Buy" belassen. Die Produktpipeline des Antikörperspezialisten stehe wieder... ► Artikel lesen | |
| ERASCA | 18,070 | +1,35 % | Jefferies reiterates Erasca stock Buy rating on rival trial data | ||
| ALLOGENE THERAPEUTICS | 2,025 | -11,18 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation ... | 41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 333,80 | -2,74 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,000 | +6,27 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer | RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities... ► Artikel lesen | |
| TANGO THERAPEUTICS | 24,530 | +1,91 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat | - Matthew Gall appointed Chief Financial Officer -- Additional key appointments add expertise in clinical operations, corporate strategy and project leadership - BOSTON, April 15, 2026 (GLOBE... ► Artikel lesen | |
| BEAM THERAPEUTICS | 30,200 | -0,43 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| ARCELLX | 115,00 | +0,10 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| MODERNA | 45,560 | +1,63 % | Moderna - MRNA: Impfstoff-Aktie mit mega-starkem Comeback! | + 100 Prozent in 6 Monaten! mrRNA-Impfstoffe gegen Krebs, Grippe & RSV bei Moderna in der Pipeline! Neue Rallye trotz US-Gesundheitsminister Robert F. Kennedy? Moderna (MRNA) - ISIN US60770K1079 Rückblick:... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,180 | +1,58 % | Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst | ||
| DYNE THERAPEUTICS | 19,710 | -0,66 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) | - New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 86,99 | -1,74 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| REVOLUTION MEDICINES | 127,45 | +2,37 % | Meilenstein im Kampf gegen Bauchspeicheldrüsenkrebs: Revolution Medicines hebt ab! | Sie gilt als eine der Krebsarten mit dem höchsten medizinischen Bedarf: Bauchspeicheldrüsenkrebs. Die Biotech-Gesellschaft Revolution Medicines, der Übernahmeinteresse von Merck & Co nachgesagt wurde... ► Artikel lesen |
PEGBIO CO LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PEGBIO CO LTD finden Sie auf Wallstreet Online.